<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627155</url>
  </required_header>
  <id_info>
    <org_study_id>LY03003/CT-CHN-101</org_study_id>
    <nct_id>NCT04627155</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Human Tolerance and Kinetics of LY03003 By Single Intramuscular Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the human tolerance and pharmacokinetics of LY03003.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2013</start_date>
  <completion_date type="Actual">May 20, 2013</completion_date>
  <primary_completion_date type="Actual">May 20, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>Hour1 、Hour6、Hour12、Hour24、Hour36、Hour48、Hour60 、Hour72 、Hour84、Hour96 、Hour120 、Hour144 、Day8、Day9、Day10、Day11、Day12、Day13、Day14、Day16、Day18 and Day 21after injection</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Hour1 、Hour6、Hour12、Hour24、Hour36、Hour48、Hour60 、Hour72 、Hour84、Hour96 、Hour120 、Hour144 、Day8、Day9、Day10、Day11、Day12、Day13、Day14、Day16、Day18 and Day 21after injection</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Hour1 、Hour6、Hour12、Hour24、Hour36、Hour48、Hour60 、Hour72 、Hour84、Hour96 、Hour120 、Hour144 、Day8、Day9、Day10、Day11、Day12、Day13、Day14、Day16、Day18 and Day 21after injection</time_frame>
    <description>Weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>7mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03003</intervention_name>
    <description>Rotigotine,extended-release microspheres</description>
    <arm_group_label>14mg dose group</arm_group_label>
    <arm_group_label>7mg dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged 18 to 45 years, no less than one-third of a single sex ratio;&#xD;
&#xD;
          2. normal physical examination items (including general physical examination, blood and&#xD;
             urine, blood biochemistry, anti-HBV, anti-HCV, anti-HIV, pregnancy test, ECG, chest&#xD;
             X-ray);&#xD;
&#xD;
          3. body weight not less than 50 kg, body mass index between 19 and 24 kg/m2;&#xD;
&#xD;
          4. during 2 weeks not using any drugs;&#xD;
&#xD;
          5. no history of drug allergy or drug allergy;&#xD;
&#xD;
          6. voluntarily participate in this clinical trial, can cooperate to complete the&#xD;
             specified examinations, and sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. abnormal health examination and clinical significance;&#xD;
&#xD;
          2. history of allergy to non-ergot dopamine agonists, or history of allergy to other&#xD;
             drugs and food;&#xD;
&#xD;
          3. Bronchial asthma, epilepsy, mechanical intestinal obstruction, urinary tract&#xD;
             obstruction;&#xD;
&#xD;
          4. history of liver and kidney disease, cardiovascular system, respiratory system,&#xD;
             hematopoietic system, nervous and mental illness;&#xD;
&#xD;
          5. Women of childbearing age who have a positive pregnancy test or a negative pregnancy&#xD;
             test but cannot ensure to take appropriate contraceptive measures during the study;&#xD;
&#xD;
          6. lactating women;&#xD;
&#xD;
          7. Male subjects who are unwilling to take appropriate contraceptive measures.&#xD;
             Appropriate measures include the use of condoms, spermicides, or female partners using&#xD;
             intrauterine devices (IUDs), ovarian caps, oral contraceptives, injected or&#xD;
             subcutaneously implanted progestins, and tubal ligation surgery. Female partners must&#xD;
             not be pregnant or lactating women;&#xD;
&#xD;
          8. smokers, alcoholics and drug abusers;&#xD;
&#xD;
          9. drinkers within 24 hours before medication;&#xD;
&#xD;
         10. used any drugs within 2 weeks before the trial; Use of drugs with effect on liver and&#xD;
             kidney function within 11.3 months; Participated in other drug trials within 12.3&#xD;
             months, donated blood loss (≥ 200ml), or sampled as subjects;&#xD;
&#xD;
        13. Researchers believe that the participants are not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LY03003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

